Company news
NeuroSense Therapeutics Ltd. news in 2025
NeuroSense Therapeutics Ltd.'s news releases, calls and decks from 2025, newest first.
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
December 22, 2025
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
December 4, 2025
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
November 24, 2025
NeuroSense to Host Investor Webinar on December 8, 2025
November 3, 2025
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
October 6, 2025
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
September 10, 2025
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
September 4, 2025
NeuroSense Provides Business Update and Progress for the First Half of 2025
July 30, 2025
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community
July 22, 2025
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
May 7, 2025
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
April 24, 2025
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment
April 9, 2025
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates
April 7, 2025
NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting
April 4, 2025
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
March 20, 2025
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
January 5, 2025